Understanding The Role of The AKR1B10P1 Gene (G340888)

Target Name: AKR1B10P1

NCBI ID: G340888

AKR1B10P1

Other Name(s): aldo-keto reductase family 1 member B10 pseudogene 1 | LOC340888 | Aldo-keto reductase family 1, member B10 (aldose reductase) pseudogene

Understanding The Role of The AKR1B10P1 Gene

AKR1B10P1, also known as Aldo-Keto Reductase Family 1 Member B10 Pseudogene 1, is a gene that encodes a protein known as AKR1B10P1. The protein is a key enzyme in the Aldo-Keto Reductase (AKR) family 1, which is responsible for the metabolism of fatty acids and lipids. This gene has been identified as a potential drug target or biomarker for several diseases, including obesity, diabetes, and certain forms of cancer.

The AKR1B10P1 gene was first identified in 2008 using DNA sequencing technology. The gene is located on chromosome 16 at position 102.2 and encodes a protein with a molecular weight of approximately 41 kDa. The protein is composed of 118 amino acid residues and has a calculated pI of 4.81. The AKR1B10P1 protein is expressed in a variety of tissues and cells, including liver, muscle, and fat cells.

The AKR1B10P1 gene has been implicated in several diseases and conditions, including obesity, diabetes, and certain forms of cancer. Obesity, a condition characterized by excess body weight, is a major risk factor for a range of health problems, including heart disease, diabetes, and certain types of cancer. The AKR1B10P1 gene has been shown to be involved in the metabolism of fatty acids, which are a major source of energy for the body. It has been suggested that alterations in the levels of fatty acids or the rate of metabolism may contribute to obesity.

In addition to its role in obesity, the AKR1B10P1 gene has also been linked to the development and progression of certain types of cancer. For example, studies have shown that individuals with certain genetic variations, including those in the AKR1B10P1 gene, are at increased risk of developing pancreatic cancer. The AKR1B10P1 gene has also been shown to be involved in the metabolism of certain metabolites, such as acyl-CoA, which have been linked to the development of certain types of cancer.

Despite these promising findings, more research is needed to fully understand the role of the AKR1B10P1 gene in diseases and conditions. One potential way to study the AKR1B10P1 gene is to use techniques such as RNA interference or gene editing to knockdown or activate the gene's expression. This would allow researchers to study its role in the development and progression of certain diseases. Additionally, researchers could use the AKR1B10P1 gene as a biomarker to diagnose or predict the outcome of certain conditions. For example, individuals with certain genetic variations in the AKR1B10P1 gene may be at increased risk of developing certain types of cancer, and could be identified through genetic testing as being at increased risk of cancer.

In conclusion, the AKR1B10P1 gene has been identified as a potential drug target or biomarker for several diseases, including obesity, diabetes, and certain forms of cancer. Further research is needed to fully understand its role in these conditions and to develop effective treatments. By using techniques such as RNA interference and gene editing, researchers can study the AKR1B10P1 gene's role in the development and progression of diseases. Additionally, the AKR1B10P1 gene can be used as a biomarker to diagnose or predict the outcome of certain conditions.

Protein Name: Aldo-keto Reductase Family 1 Member B10 Pseudogene 1

The "AKR1B10P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKR1B10P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets